April 1, 2021
By Bio-IT World Staff
April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.
$969M Investment Fund for Early to Late-Stage Companies
Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversubscribed above its original target. The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market. Foresite Capital now has ~$4 billion in assets under management. Press release.
Theator Nabs $15.5M to Scale AI-Driven Surgical Intelligence Platform
What You Should Know:
– Theator raises $15.5M in Series A funding to support the company’s mission of using AI and computer vision to eradicate disparity and variability in surgical care.
– The startup plans to use this round to scale its commercial operations and partnerships with U.S. providers, grow its R&D team and cement its status as a world-leading provider of AI-powered Surgical Intelligence solutions.
Theator, a Palto Alto, CA-based Surgical Intelligence platform leveraging AI and computer vision to improve surgeon performance, today announced that it has raised $15.5M in an oversubscribed Series A round led by Insight Partners, joined by new investor Blumberg Capital, and supported by all existing investors including NFX, StageOne Ventures, KdT Ventures, and iAngels. Several notable individual investors, including 23andMe’s Co-founder and CEO Anne Wojcicki, former Netflix Chief Pro